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Abstract         
The weakness in myasthenia gravis (MG) is mediated by autoantibodies against adult 
muscle acetylcholine receptors (AChR) at the neuromuscular junction; most of these 
antibodies also bind to fetal AChR which is present in the thymus. In rare cases, babies of 
MG mothers, or even of asymptomatic mothers, develop a severe developmental condition, 
arthrogryposis multiplex congenita (AMC), due to antibodies that inhibit the ion channel 
function of the fetal AChR, whilst not affecting the adult AChR.  Here we show that these 
fetal AChR inhibitory antibodies are significantly more common in females sampled after 
pregnancy than in those who present before pregnancy, suggesting that they may be 
induced by the fetus.  Moreover, we were able to clone high-affinity combinatorial Fab 
antibodies from thymic cells of two MG mothers with AMC babies.  These Fabs were highly 
specific for fetal AChR and did not bind the main immunogenic region (MIR) that is common 
to fetal and adult AChR.  The Fabs show strong biases to VH3 heavy chains, and to a single 
Vκ1 light chain in one mother.  Nevertheless, they each show extensive intraclonal 
diversification from a highly mutated consensus sequence, consistent with antigen-driven 
selection in successive steps.  Collectively, our results suggest that, in some cases of MG, 
initial immunization against fetal AChR is followed by diversification and expansion of B cells 
in the thymus; maternal autoimmunity will result if the immune response spreads to the main 
immunogenic region and other epitopes common to fetal and adult AChR. 
 
Abbreviations:- α-BuTx, α-Bungarotoxin: AChR, acetylcholine receptor: AMC, arthrogryposis 
multiplex congenita: CDR, complementarity-determining region: EOMG, early-onset 
myasthenia gravis: FWR, framework: GC, germinal center(s): MIR, main immunogenic 
region: R:S, replacement: silent. 
 
Keywords: acetylcholine receptor, fetal antigen, arthrogryposis multiplex congenita, 
myasthenia gravis, autoimmunity 
  Matthews 3
Introduction 
Autoimmune disorders collectively cause much suffering and disability and many are 
particularly common in women of child-bearing age. The muscle weakness in the majority of 
myasthenia gravis (MG) patients results from autoantibodies to the acetylcholine receptor 
(AChR) which cause AChR loss, mainly by complement-mediated damage to the post-
synaptic membrane and/or accelerated AChR degradation (reviewed by Drachman,1994), 
Willcox and Vincent,1988).  The AChR consists of two α subunits and one β, γ and δ in the 
fetus (Unwin, 2000). Together, these subunits form a cation-specific ion channel that opens 
when ACh binds to the two sites at the α/δ and either the α/γ or α/ε interfaces (Unwin, 2000).  
From about 30 weeks’ gestation in humans, the ‘adult’-specific ε subunit gradually replaces 
the γ subunit (Hesselmans et al, 1993), but the fetal isoform continues to be expressed on 
rare myoid cells in the adult thymic medulla (Schluep et al, 1987).   
 Early-onset MG (before age 40; EOMG) shows a ~3:1 female bias and a strong HLA-
DR3-B8 association.  The thymus is apparently an important site of autoimmunization 
(Drachman, 1994; Willcox and Vincent 1988; Kornstein et al, 1984; Bofill et al, 1985; 
Schluep et al, 1987; Sims et al, 2001);  thymectomy is often beneficial and, in most EOMG 
cases, the thymus is invaded by lymph node-like T cell areas and germinal centers (GC; 
(Willcox and Vincent, 1988; Bofill et al 1985; Kornstein et al 1984), many of which show 
AChR-specificity (Sims et al 2001).  GC are well known sites of B cell memory generation 
and of antibody diversification by antigen-selection of somatic variants (Sims et al 2001; 
MacLennan 1994).  Moreover, there is selective activation of thymic plasma cell responses, 
with spontaneous production of anti-AChR antibodies (Willcox and Vincent 1988), which 
show specificities similar to those in the patients’ blood (Heidenreich et al 1988).  The anti-
AChR antibodies in typical MG patients are very heterogeneous (Vincent et al 1987) and 
antibodies cloned from the thymus of typical EOMG patients show a range of specificities 
resembling those in the donors’ sera (Graus et al 1997; Farrar et al 1997; Serrano et al 
1994).   
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 About 8% of MG mothers have babies with transient neonatal MG, and their sera 
tend to have higher antibody titers against fetal than adult AChR (Vernet der Garabedian et 
al 1994), consistent with a role for thymic AChR in inducing their disease.  In some rare 
examples, babies of MG mothers are born with severe developmental abnormalities, usually 
described as arthrogryposis multiplex congenita (AMC; reviewed in Hall and Vincent, 2001), 
which includes multiple joint contractures, hypoplasia of the lungs, other malformations and 
often fetal or neonatal death. The serum of these MG mothers, and others who are 
asymptomatic (Vincent et al 1995), contains antibodies that strongly and very selectively 
inhibit the ACh-triggered ion channel function of fetal AChR (Riemersma et al 1997). These 
inhibitory antibodies persist in the maternal circulation and can transfer a similar condition to 
the pups after injection into pregnant mice (Jacobson et al 1999a).   Interestingly, the first 
child of mothers of AMC babies is often unaffected and, when present, MG may not be 
clinically evident in the mother at the time of the first affected birth (see Polizzi, Huson and 
Vincent, 2000), suggesting that the maternal immune system may first be sensitized to 
AChR from the fetus.   Moreover, the dominance of fetal AChR-specific antibodies in these 
women (Riemersma et al 1997) suggested that the B cell response might be clonally 
restricted.  
Here we examined the relationship between inhibitory antibodies and parity in MG 
patients, and then took advantage of the fact that EOMG patients are treated by 
thymectomy, providing us with thymic B cells and plasma cells from which to clone and 
recombine fetal-AChR specific antibodies.  We selected combinatorial Fabs from  two MG 
mothers with high levels of fetal AChR-specific antibodies, whose babies had severe AMC. 
These Fabs proved to be strongly biased towards fetal AChR and were each dominated by 
one clone with extensive somatic diversification from an already highly mutated consensus 
sequence.  These results suggest that the fetus could be responsible for immunizing the 
mother during pregnancy, with further diversification occurring subsequently in the thymus. 
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Results 
Antibodies inhibiting fetal AChR function in MG.  We searched our records for women with 
MG who had had children before their first available serum sample.  We found twelve 
women with generalized MG who had had 1-3 children each by the time of sampling, which 
was before thymectomy or immunosuppressive treatment (Parous MG; see Table 1); in all 
but one case, MG presented during or after pregnancy.  We compared the results with those 
of 12 women who had not had children at the time of sampling (Non-parous MG), 11 male 
MG patients and 12 healthy controls.  Two AMC-M sera were used as positive controls. As 
expected, the age at MG onset was higher in the Parous MG than the Non-parous MG 
women (mean ± SD; 30.7 ± 7.8 compared with 19.9 ± 5.3), but there was no substantial 
difference in the total levels of anti-AChR antibodies on routine testing (22.26 ± 10.6 nM 
compared with 26.05 ± 12.7 nM).  Male MG patients were of a similar age to parous females 
(30.9 ± 8.4) and with similar anti-AChR values (18.5 ± 12.7). To assay the levels of fetal-
AChR inhibitory antibodies, we measured the effects of the sera on agonist-induced 22Na 
flux into TE-671 cells. Healthy sera did not inhibit flux appreciably (0.02 ± 0.58% compared 
to results in Hepes-Locke buffer alone).  Inhibition of flux by the Parous MG sera was 
greater than that by the Non-parous (p=0.023; Mann Whitney one-tailed; Fig 1) or male MG 
sera. These results suggest that pregnancy can influence the specificity of AChR antibodies 
in MG patients, and may initiate the response in some susceptible individuals.  
 
Cloning anti-AChR Fabs from thymic combinatorial libraries.  In order to examine the clonal 
origins of fetal-specific AChR antibodies, we characterized Fabs cloned from unamplified 
VH/Vκ cDNA libraries prepared from  thymic cells of AMC-M2 and AMC-M6, after screening 
2.0-2.5 x 105 clones.  It was relatively easy to detect AChR-specific plaques by blotting the 
expressed Fabs with 125I-αBuTx-AChR solubilized from human muscle, and to clone the 
positives by further rounds of screening (Fig 2a); the results are summarized in Table 2.  
Fetal AChR inhibitory antibodies competed with one of the two α-BuTx-binding sites 
(Riemersma et al 1997), leaving the second site available for detection with 125I-α-BuTx.  
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Therefore, in order to clone Fabs that might compete with α-BuTx for binding to the fetal 
AChR, we re-screened the AMC-M2 library with unlabeled muscle extract, allowing the 
AChR to bind before we applied the 125I-α-BuTx.  A further 25 clones were thus isolated and 
two characterized in detail. We also prepared a parallel VH/Vλ library from AMC-M2 and 
isolated another 25 clones (Table 2). 
 
Specificity of AMC-M Fabs for fetal AChR.  Both AMC-M2 and AMC-M6 libraries yielded 
Fabs that efficiently immunoprecipitated 125I-α-BuTx-human AChR, in most cases 
precipitating all of the available receptor.  Examples of titrations of the Fabs are shown in Fig 
2b and c; the efficient binding by monomeric Fabs of soluble AChR (at ~500 pM final 
concentration) indicates a high affinity. The muscle extracts used for screening and 
precipitations were from amputees with ischemic disease; although these have a 
preponderance of fetal over adult AChR (Vincent and Newsom-Davis 1984), antibodies to 
the α, β or δ subunits bind similarly to both isoforms (Tzartos et al 1998; Fostieri, Beeson 
and Tzartos 2000).  We therefore tested the Fabs against AChR extracted from TE671 cells 
that express only fetal AChR, or from a TE671 subline that expresses predominantly (>90%) 
adult AChR (Beeson et al 1996). The two AMC-M sera preferred the fetal isoform, although 
they also showed some reactivity with adult AChR (Figure 3a).  However, all of the Fabs, 
with one exception (Fab 8H/K from AMC-M6), bound almost exclusively to fetal AChR.  Even 
the low apparent reactivity with the adult AChR preparation could be due to the remaiing 
10% of fetal AChR (Beeson et al 1996). 
 To confirm this striking finding, we also tested the Fabs’ ability to block the binding of 
mAbs specific for human fetal AChR γ subunits. Both AMC-M2 and AMC-M6 serum 
antibodies blocked binding of each of the two mAbs specific for fetal AChR (Figs 3b and c), 
as did all the Fabs except 8K from AMC-M6, which instead blocked binding of the mAb with 
β subunit-specificity (Fig 3c).  These experiments confirm  the high affinity for fetal AChR of 
the Fabs and most of the serum antibodies, and their probable γ subunit-specificity. 
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 It was also important to test the Fabs for inhibition of fetal AChR ion channel function.  
Disappointingly, only Fab 35K from AMC-M2 showed appreciable activity and that only at 
relatively high Fab concentrations (50% inhibition at 100 μl of Fab).  There was no effect on 
adult AChR (data not shown).  In parallel experiments, cross-linking the cloned Fabs with 
secondary antibodies did not increase the degree of inhibition.  Indeed, inhibition of function 
did not require divalent antibodies, since it was readily measurable with monovalent Fabs 
prepared from both donors’ serum Ig (data not shown). 
 
Sequences of the AMC-M2 Fab VH and Vκ genes.  The V-genes were sequenced and 
compared with those in the human Ig VBASE directory (Tomlinson et al 1997) to identify 
both the closest germline sequence and the number of somatic mutations (Table 3).  All the 
AMC-M2 Fabs were specific for fetal AChR and used the same VH3-07/D?/JH6b 
combination, regardless both of the screening procedure used to identify them (Table 2) and 
of their exact κ (Table 3)  or λ light chain partner (not shown). They had the same CDR3 
length and the majority shared 32 ‘consensus’ VH mutations, demonstrating a common 
clonal origin from a previously-mutated progenitor. Replacement:silent (R:S) ratios were 
higher in the first two hypervariable (CDR) loops than in the framework regions (FWR), 
strongly suggesting antigen-driven selection for antibody specificity/affinity. 
 By contrast, the AMC-M2 kappa light sequences were heterogeneous; despite their 
similar binding specificity, these Fabs used a variety of Vκ (Table 3), which varied 
substantially both in numbers of mutations and R:S ratios. Although two Fabs used the Vκ 
02/12 gene, their different Jκ usage demonstrates that they are independent gene 
rearrangements. This contrasting VH restriction and Vκ diversity suggests that the heavy 
chain was primarily responsible for the fetal AChR-binding specificity. 
 
Recurring VH and Vκ usage by AMC-M6 Fabs.  Table 3 also summarizes the genes 
encoding the second donor’s anti-AChR Fabs. Fab 8H/K is the first human AChR β subunit-
specific autoantibody to be cloned. It uses the relatively uncommon VH4-61 gene in 
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combination with the commonly expressed VK1 02/12 Vκ gene. Both the heavy and light 
chains are highly mutated, with higher R:S ratios in the CDR than the FWR regions (Table 
3).  One of the fetal AChR-specific Fabs (Fab 1H/K) used a highly mutated VH3-
23/DH3.3/JH6b plus a Vκ4 B3/Jκ 3 gene (Table 3). All of the others used the same pair of 
VH3-21/D?/JH5b heavy and Vκ 02/12 light chain genes, again with Jκ4 (Table 3); the 
frequency of base differences between these sequences is significantly above the PCR error 
rate for the Taq polymerase used (Chazenbalk et al 1993), but the VHs and Vκs are clearly 
clonally-related.    
 The extent of somatic mutation shows that each is clearly derived from a highly 
mutated progenitor (with 44 consensus substitutions in the VH and 25 in the Vκ). The R:S 
ratios for the heavy chain gene are moderate, because the number of VH mutations 
approaches saturation (often 2 or even 3 per codon). Their closest germline counterparts 
and their clonal relationships are shown in Fig 4; the pattern is essentially similar for the VH 
sequences of the AMC-M2 Fabs (not shown). In the genealogical trees for both heavy and 
light chains, the branching patterns, with variable numbers of successive mutations 
separating each sequence, are clear evidence of further antigen-driven clonal proliferation 
and somatic mutation;  moreover each stems from an already-mutated progenitor. Notably 
also, since neither this heavy nor this light chain was found with other partners, they could 
both be derived from the same progenitor B cell. 
 
Convergent mutations suggesting common fetal AChR-specific selection processes.  We 
saw recurring replacements in the three independent fetal AChR-specific VH3 genes and 
especially in the Vκ 02/12 sequences. In brief, there was a CDR1 31S→T substitution in all 
VH3 Fabs from AMC-M2 and AMC–M6.   Even more strikingly, among the Vκ 02/12 light 
chains, AMC-M2 13K and the majority of the AMC-M6 Fabs not only use Jκ4 but also have 
common 22T→S, 27Q→E, 28S→T and 53S→T replacements. The former three contribute to 
the CDR1 to form a 22SRASET28 motif that is found in only two other human κ sequences in 
GenBank. Moreover, these recurring H and L chain mutations were not seen in another fetal 
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AChR-specific Fab from a non-parous EOMG female (Farrar et al 1997) or in the very 
different AChR β-specific Fab-8 from AMC-M6 (data not shown).    
  
Discussion 
We have shown, for the first time, that antibodies inhibiting the ion channel function of fetal 
AChR are common not only in mothers of AMC babies (Riemersma et al 1997), but also in 
women who developed MG after pregnancy.  By contrast, such antibodies were uncommon 
in women who presented before pregnancy.  In addition, the many high affinity Fabs that we 
cloned from the thymus of two AMC mothers showed a very strong preference for fetal 
AChR and a biased usage of VH3 genes. The striking diversification of the Fabs in each 
woman from a common, but already highly mutated, germ-line sequence, shows that the 
autoantibodies can arise via successive rounds of antigen-driven selection in a few clones. 
These results suggest a scenario in which oligoclonal responses to fetal AChR, including 
some that block fetal AChR function, are the initiating event in women who develop MG after 
pregnancy, irrespective of whether the level of these antibodies is sufficient to cause AMC.  
Immunization by the fetus is, therefore, another possible contributory factor to the female 
bias evident in many autoimmune diseases, in addition to the established hormonal 
influences (Whittacre  2001) and the possible rôles of fetal↔maternal microchimerism (Hall 
et al 1995; Maloney et al 1999; Nelson 2001).  
 The Fabs that we cloned from the two unrelated AMC-mothers show remarkable 
similarities.  They clearly have high affinities, since they immunoprecipitate AChR at ~500 
pM and, despite being monomeric, they also efficiently block binding of bivalent mAbs. In 
theory, the predominance of fetal AChR in the ischemic muscle extracts we used (Vincent 
and Newsom-Davis 1984) might have created a bias in screening towards fetal AChR-
binding Fabs.  However, the MIR on the α subunits is thought to be the target of the majority 
of AChR antibodies in MG (Tzartos et al 1998); although some may have a preference for 
the fetal isoform (Fostieri, Beeson and Tzartos 2000), we should also have been able to 
detect them with adult AChR, and to inhibit them with the anti-MIR mAb. In fact, the almost 
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exclusive recognition of fetal, rather than adult, AChR contrasts sharply with Fabs cloned 
from the thymus of a more typical non-parous young female MG patient under the same 
conditions. In Farrar et al (1997) we obtained four distinct Fabs; three of them bound adult 
and fetal isoforms impartially and competed with mAbs specific for the main immunogenic 
region (MIR) on the alpha subunits.  Only the fourth, which used another VH3 gene, DP58, 
showed similar fetal-AChR specificity to the present Fabs.  In another study which also used 
predominantly fetal AChR for selection (Graus et al 1997), only anti-MIR Fabs were 
obtained. Thus we do not feel that the selection with ischaemic muscle AChR explains the 
bias towards fetal AChR. Although we were not able to generate a library from a control 
thymus, in a study of Fabs derived from an MG thymoma library, we found only one with 
AChR reactivity but a large number binding to interferon alpha, apparently reflecting the 
spontaneous production of anti-interferon alpha antibodies but not AChR antibodies by the 
patient’s thymic lymphocytes (H Shiono, Y Wong, Willcox and Vincent, in preparation).  Thus 
the selection process is antigen-specific and depends on the presence of the relevant heavy 
and light chain genes in the thymic tissue. 
 We had hoped to clone Fabs that inhibited fetal AChR ion channel function, since 
these antibodies are clearly present in the AMC-M sera (Riemersma et al 1997) and in 5/12 
of the parous-MG women, and we found that monomeric serum Fabs retain inhibitory 
activity. Although the main ACh-binding sites are on the α subunits, they lie at the α/δ and 
α/γ interfaces: the distinctive α/γ site of the fetal isoform appears to be the target for the 
inhibitory antibodies (Riemersma et al 1997). Similar antibodies were found in one MG 
serum using rat fetal AChR in an early study (Weinberg and Hall 1979), although they bound 
to both adult and fetal isoforms when human AChR was used (Burges et al 1990).  These 
inhibitory antibodies compete with 125I-α-BuTx for binding to one of its two sites, making their 
detection with 125I-α-BuTx-AChR more difficult, although we tried to overcome this difficulty 
by overlaying the filters with unlabeled AChR and adding 125I-α-BuTx subsequently.  
However, despite their potency in causing AMC, they constitute only about 5% of the total 
anti-AChR antibodies in either these patients’ thymic culture supernatants (not shown), or 
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their sera (A Vincent, unpublished calculations from data in Riemersma et al 1997).  This 
probably explains their rarity among our cloned Fabs. 
 The efficient screening and cloning of Fabs binding specifically to fetal AChR implies 
a striking dominance of this specificity in the AMC mothers’ thymic cells. Furthermore, we 
found a single dominant family of clonally related Vκ sequences in AMC-M6 and of VH3 
sequences in both patients. In AMC-M2, the same clonally related VH3-07 sequences 
predominated whether they were isolated together with κ or λ light partners and irrespective 
of the screening procedure used (Table 2). A parallel restriction in Fabs recognizing a 
minority epitope, contrasting with heterogeneity of those against a dominant region, has 
recently been reported for thyroid peroxidase in a patient with Graves’ disease (Pichuri et al 
2001). The VH3 germline genes of our two clonal families are both commonly used by 
normal blood B cells (de Wildt et al 1999), as is the Vκ1 02/12 that predominated in AMC-M6 
and recurred in AMC-M2 (De Wildt et al 1999; Foster et al 1997). A PCR bias seems very 
unlikely since the five non-specific Fabs isolated from our AMC-M2 VH/Vκ library did not 
include the VH3-07, VH3-21 or Vκ1 02/12 genes and VH3 genes are not over-represented in 
Fabs cloned, using the same primers, from other MG patients against other antigens (Y 
Wong, N Willcox and A Vincent unpublished observations) or from autoimmune thyroid 
tissue (Chazenbaik et al 1993; Guo et al 1999). 
 Since the dominant VH3-07 used by AMC-M2 was paired with so many unrelated 
light chains (both κ and λ), its VH probably makes the major contribution to binding 
specificity, as has frequently been observed with other antibodies (Guo et al 1999; Weigert 
and Potter 1977; Collet et al 1992; reviewed in Dorrington and Tanford 1970; Winter et al 
19945).  With AMC-M6, by contrast, the recurring usage of highly mutated and clonally 
related light chains in exclusive combination with the dominant VH3-21 suggests that they 
also have a major influence on specificity (as reviewed By Weigert and Potter 1977).  There 
are long-established precedents for that in certain heritable restricted responses in mice to 
well defined epitopes (Weigert and Potter 1977), and also in human autoantibodies (Hoet et 
al 1999). 
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 Importantly, the deduced ancestral sequence for each of the dominant families is 
already highly mutated (with 32, 44 and 25 shared differences from germline for AMC-M2 
and AMC-M6 VH, and AMC-M6 Vκ respectively) indicating that the progenitor B cells had 
already undergone antigen-selection in GC before further refinement in the thymus.  Almost 
all of the present sequences show multiple mutations, especially in the CDRs where 
replacement:silent ratios were often high. Of particular interest is the evidence of convergent 
mutations in the two patients’ VH and especially in the recurrent 22SRASET28 sequences in 
Vκ, suggesting that these Fabs may be recognizing a dominant fetal AChR epitope. 
Together with the abundant mutations, the high R:S ratios in the CDRs, and the branching 
patterns of their evolution, these results strongly suggest that each Fab is the end-product of 
successive stages of antigen-driven clonal proliferation in GC, as also found after 
Haemophilus vaccination in subjects with preexisting B cell memory (Hougs et al 1999).  
One can envisage that, over the preceding years, and four and two pregnancies 
respectively, the memory B cells that were initially generated could re-activate and/or re-
enter GC for further rounds of mutational refinement. The striking patterns of oligoclonal 
evolution/diversification that we have observed in the fetal AChR-specific Fabs from both 
AMC mothers, are very reminiscent of those noted in a mouse model with spontaneous SLE, 
where a surprising variety of specificities stemmed from remarkably few ancestral B cells 
(Shlomchik et al 1987).  
On the basis of these results, we suggest the initial immunization is by the fetus, 
generating a restricted group of mutated ‘progenitor’ memory cells, possibly in lymph nodes 
draining the uterus. Consequently, circulating antibodies are produced against fetal AChR; 
they attack rare myoid cells in the thymus that express this isoform (Schluep et al 1988), 
releasing antibody:AChR complexes that provoke local GC formation very efficiently 
(MacLennan 1994; Kunkl and Klaus 1981). The progenitor memory cells are attracted by the 
complexes trapped in these GC, and undergo further rounds of mutation and selection, 
culminating in the expanded populations of clonally related B cells and plasma cells that we 
have detected (Table 3, Fig 4). Independent evidence has already strongly implicated myoid 
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cells in GC formation in 36 EOMG thymic samples, including AMC-M2 and -M6 (I Roxanis, N 
Willcox, in preparation), as well as GCs in diversification of IgG antibodies in MG (Sims et al 
2001).  
 Several autoimmune diseases show both a strong female bias and onset in early 
adulthood (eg SLE, thyroid disease, multiple sclerosis and EOMG); there is evidence for the 
importance of hormonal influences in the autoimmune response, as well as potential X 
chromosome contributions in these diseases (Whitacre 2001).  Persisting fetal ↔ maternal 
microchimerism has also been invoked because of the recent findings of fetal or maternal 
RNA in scleroderma lesions (discussed in Maloney et al 1999; Nelson 2001). There are 
already well known examples of alloimmunization of mothers, for example, by fetal 
erythrocytes or platelets (Blanchette, Johnson and Rand 2000). While it might be informative 
to look for allotypic variations in the AChR γ subunit, the AChR is remarkably 
autoimmunogenic, even without adjuvant (Jermy, Beeson and Vincent 1993).  Although the 
majority of EOMG female patients present before pregnancy, our results suggest that 
autoimmunization by the fetus is another possible route to maternal MG, perhaps enhanced 
by presentation by semi-allogeneic (fetal) cells.   
 
Methods 
Clinical material. Patient material was obtained with informed consent and Ethical 
Committee approval.  Sera from MG patients were collected in Professor John Newsom-
Davis’ clinic, before thymectomy or immunosuppression, and stored at –20°C. Antibodies to 
AChR were measured as previously described (Vincent et al 1995; Riemersma et al 1997).  
AMC-M2 and AMC-M6, described in (Riemersma et al 1997; Jacobson et al 1999a), had 
had four and two babies, respectively, with severe AMC (fatal in all but one), but the 
diagnosis of maternal MG was made only after the birth of the AMC babies. After therapeutic 
thymectomy and immunosuppressive therapies for their MG, and plasma exchange during 
pregnancy, both mothers have subsequently had successful pregnancies with minimally 
affected babies (unpublished observations).   Thymus cell suspensions were prepared and 
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cryopreserved as in (Willcox, Newsom-Davis and Calder 1983). From both patients, these 
cells spontaneously produced high levels of anti-AChR antibodies in culture that were 
reduced by pokeweed mitogen, typical of plasma cell behavior (Willcox, Newsom-Davis and 
Calder 1983); these antibodies showed a strong preference for fetal AChR, and also 
inhibited its ion channel function (not shown), as did serum antibodies from AMC-M2 
(Riemersma et al 1997) and AMC-M6. 
 
Measurement of inhibition of AChR function in TE671 cell line. We measured AChR function 
in TE671 cells that express only fetal AChR, as previously described in (Riemersma et al 
1997).  Carbachol-induced 22Na+ flux was measured over 1 minute, and the internalized 
22Na+ was counted on a Packard Autogamma counter. The inhibitory effect of the sera was 
tested by incubating the cells with 25 μl of serum in 500 μl Hepes Locke buffer (ie. 1:20) for 
30 minutes.  The results are expressed as % inhibition, with 0% being the cpm in Hepes 
Locke buffer alone and 100% inhibition being the cpm in cells tested in the presence 1 μg/ml 
of the antagonist α-bungarotoxin (α-BuTx).  Those sera producing more than 50% inhibition 
were then retested at higher dilutions and the results are presented as % inhibition/μl of 
serum. 
 
Combinatorial Ig gene library construction.  The Fab library was made from cDNA after 
reverse-transcription from mRNA obtained from thymic cells (Farrar et al 1997). We used an 
anti-sense primer for an IgG1 CH1 sequence (almost identical to its IgG3 homolog (Kabat et 
al 1991)) to amplify VH chain cDNA by PCR in combination with a panel of sense 
oligonucleotide primers designed to include VH1-VH6 gene families: further panels amplified 
the Vκ or Vλ gene families, as described in (Farrar et al1997).  The PCR products were 
ligated into Immunozap H or L bacteriophage vectors (Stratagene).  Subsequently, the 
heavy and light chain DNAs were ligated into Immunozap to yield  combinatorial libraries, as 
detailed in (Farrar et al 1997) and (Chazenbaik et al 1993).  
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Screening the library for AChR-binding Fabs.  Positive clones were identified essentially as 
in (Farrar et al 1997).  Muscle extracts from denervated muscles were labeled with 2 nM 125I-
α-BuTx (Amersham International, Amersham, UK; specific activity 2000 Ci/mmol) and used 
to screen the unamplified combinatorial library in XL1-Blue cells by filter-lift assays.  Positive 
plaques were identified by autoradiography, cloned to homogeneity, and the heavy and light 
chain genes were sequenced in both directions by the dideoxy chain termination method 
(Sanger et al 1977).  To obtain soluble Fabs, the XL1-Blue cells were induced with 1 mM 
isopropyl-thio-galacto-pyranoside (Sigma, St Louis, MO) overnight.  The cells were then 
pelleted and freeze/thawed in 10 mM Tris buffer pH 8.0 containing protease inhibitors (see 
(Farrar et al 1997)).  The suspension was sonicated and cleared by centrifugation, to leave a 
Fab-containing lysate. 
 
Characterizing Fab reactivity with AChR. The lysates were used without further purification.  
They were incubated with AChR (either from muscle extracts, from TE671 cells or from a  
transfected subline that expresses predominantly adult AChR (Beeson et al 1996)), labeled 
with 125I-α-BuTx.  After 2 hours at 20˚C, carrier normal human serum was added plus a goat 
anti-human IgG (Lawrance Laboratories, Western Australia) which precipitated the Fab-
AChR complexes efficiently.  Competition with mAbs (Jacobson et al 1999b) was measured  
by preincubating the 125I-α-BuTx-AChR with 50 μl of each  Fab overnight at 4˚C and then 
adding excess (0.1 μl of ascites) of each mAb (see (Farrar et al 1997)).  Sheep antibody to 
mouse IgG (which did not precipitate human Fabs) was then added to precipitate mAb-
AChR complexes.  All results were compared with precipitation in the presence of a control 
Fab that did not bind AChR, and expressed as the  % inhibition by each Fab of the binding 
of the indicated mAb (see also (Whiting et al 1986)).   
 
Bioinformatics.  Sequences were compared with the human VBASE directory of 
immunoglobulin genes (Tomlinson et al 1997) using DNAPLOT (Müller, W. Institut für 
Genetik, Köln) to determine the best matching germline V-gene segments.  Sequences with 
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the same gene rearrangement and common CDR3s were judged to be clonally related.  The 
numbers of somatic mutations over the VH and Vκ regions were determined, and ratios of 
replacement to silent mutations (R:S ratio) were calculated for framework (FWR) and 
complementarity- determining regions (CDR).  Amino acid numbering and FWR and CDR 
positions were previously  defined by Kabat et al (1991).   Genealogical trees were 
constructed for sets of related genes by analysis of shared and unshared mutations using 
phylogenetic analysis using parsimony (PAUP) (Swofford 1993).  Independent genes were 
also compared for the occurrence of convergent mutations. 
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Figure legends 
Figure 1  Inhibition of fetal AChR function by sera from AMC-M2 and AMC-M6, from different 
groups of MG patients and healthy controls.  Carbachol-induced 22Na+ uptake into TE671 
cells was measured after preincubation in each of the sera, with dilutions from 1:20 to 1:500.  
The inhibition of 22Na+ uptake was expressed as a % of that obtained in the presence  of α-
BuTx, an irreversible antagonist of AChR function.  Preliminary data were presented in 
Vincent et al 2001. 
 
Figure 2   AChR binding by Fab clones.  (a) Example of immunoblot plaque lifts to detect 
Fab clones binding 125I-α-BuTx-AChR extracted from ischemic human leg muscle.  (b) 
Immunoprecipitation of 125I-α-BuTx-AChR by representative cloned Fabs from AMC-M2 and 
(c) from AMC-M6. 
 
Figure 3   Specificity of cloned Fabs.  (a) Reactivity of AMC-M2 and AMC-M6 serum 
antibodies and representative Fabs with adult and fetal AChR.  The AChRs were obtained 
from TE671 cells (fetal AChR) and from TE671 cells transfected with excess of the AChR ε 
subunit (providing approximately 90% adult AChR and 10% fetal AChR).  (b) Competition of 
AMC-M2 serum and Fabs with mAbs directed against the indicated AChR subunit. All of the 
Fabs inhibited the binding of mAbs specific for the γ subunit (c) Competition of AMC-M6 
serum and Fabs with mAbs, as above.  All but one of the Fabs inhibited binding of mAbs 
specific for the γ subunit, the other only inhibited binding to a mAb specific for the β subunit.  
The characterization of the mAbs is detailed in Jacobson et al 1999b. 
 
Figure  4  Evolution of VH and VK clones from AMC-M6. 
Sequence alignments and genealogical trees for (a) AMC-M6 VH3-21 heavy chain and (b) 
VK1 O2/12 kappa chain genes.  The Fab nucleotide sequences were aligned with the best-
matching germline genes. Only codons at which mutations occur are shown, and any amino 
acid changes are indicated above. The most parsimonious genealogical trees were 
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determined on the basis of shared and unshared mutations using the PAUP program 
(Swofford 1993). Fab names are shown in the circles with H referring to the heavy chain and 
K referring to the kappa chain. Dotted circles refer to hypothetical intermediates. Numbers 
beside arrows show the minimum number of substitutions required at each step (which may 
include multiple changes at a single nucleotide position).  
